Key result
LVH linked to ~2-fold higher prevalence of AF in thyrotoxicosis.
Why the study?
Factors increasing the risk of atrial fibrillation at thyrotoxicosis and its persistence after restoration of euthyreosis remain incompletely defined despite new diagnostic methods and mathematical analysis.
Observational (n=391)
No
LVH may flag higher AF risk in thyrotoxicosis; leaves open whether it is causal or warrants targeted screening.
Atrial fibrillation is a frequent violation of a heart rhythm at thyrotoxicosis and it can determine serious complica tions (tromboembolia, stroke) and death. The study of factors increasing risk development of atrial fibrillation at thy rotoxicosis is investigating many years but the occurrence of new diagnostic methods and mathematic analysis allows to reveal new determinants of development of atrial fibrillation and its persistence after restoration of euthyreosis. In our research we’ve studied the Echocardiography parameters in 254 normotensive patients with a thyrotoxicosis Graves’ disease without any CVD and 110 patients with a subclinical thyrotoxicosis. We detected new factors of risk of atrial fibrillation: the duration of thyrotoxicosis and the left ventricular concentric hypertrophy. The contribution of different factors in development of atrial fibrillation is defined.
No takes yet. Share an insight, caveat, or question.
Babenko et al. (2013) conducted an observational in Thyrotoxicosis (Graves' disease and subclinical) (n=391). Left ventricular hypertrophy (LVH) vs. Absence of left ventricular hypertrophy was evaluated on Prevalence of atrial fibrillation (p=0.001). In patients with thyrotoxicosis, the presence of left ventricular hypertrophy significantly increased the prevalence of atrial fibrillation compared to those without hypertrophy (26.8% vs 13.6%, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: